X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs CADILA HEALTHCARE - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA CADILA HEALTHCARE SANOFI INDIA/
CADILA HEALTHCARE
 
P/E (TTM) x 37.1 17.6 210.4% View Chart
P/BV x 7.0 4.0 175.1% View Chart
Dividend Yield % 0.5 1.0 52.9%  

Financials

 SANOFI INDIA   CADILA HEALTHCARE
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
CADILA HEALTHCARE
Mar-18
SANOFI INDIA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs4,945558 886.2%   
Low Rs3,901362 1,079.1%   
Sales per share (Unadj.) Rs1,081.8116.3 930.3%  
Earnings per share (Unadj.) Rs141.617.9 792.2%  
Cash flow per share (Unadj.) Rs185.923.1 803.8%  
Dividends per share (Unadj.) Rs33.003.50 942.9%  
Dividend yield (eoy) %0.70.8 98.0%  
Book value per share (Unadj.) Rs868.885.4 1,017.1%  
Shares outstanding (eoy) m23.031,023.74 2.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.14.0 103.4%   
Avg P/E ratio x31.225.7 121.4%  
P/CF ratio (eoy) x23.819.9 119.7%  
Price / Book Value ratio x5.15.4 94.6%  
Dividend payout %23.319.6 119.0%   
Avg Mkt Cap Rs m101,862470,664 21.6%   
No. of employees `0003.211.8 27.4%   
Total wages/salary Rs m3,68518,545 19.9%   
Avg. sales/employee Rs Th7,691.910,072.7 76.4%   
Avg. wages/employee Rs Th1,137.71,569.1 72.5%   
Avg. net profit/employee Rs Th1,006.51,547.7 65.0%   
INCOME DATA
Net Sales Rs m24,914119,049 20.9%  
Other income Rs m8071,132 71.3%   
Total revenues Rs m25,721120,181 21.4%   
Gross profit Rs m5,37228,475 18.9%  
Depreciation Rs m1,0225,388 19.0%   
Interest Rs m11911 1.2%   
Profit before tax Rs m5,14623,308 22.1%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8865,644 33.4%   
Profit after tax Rs m3,26018,292 17.8%  
Gross profit margin %21.623.9 90.1%  
Effective tax rate %36.624.2 151.4%   
Net profit margin %13.115.4 85.2%  
BALANCE SHEET DATA
Current assets Rs m14,43282,005 17.6%   
Current liabilities Rs m6,01060,720 9.9%   
Net working cap to sales %33.817.9 189.1%  
Current ratio x2.41.4 177.8%  
Inventory Days Days6173 83.3%  
Debtors Days Days2898 29.0%  
Net fixed assets Rs m7,99183,703 9.5%   
Share capital Rs m2301,024 22.5%   
"Free" reserves Rs m19,77886,421 22.9%   
Net worth Rs m20,00887,445 22.9%   
Long term debt Rs m025,551 0.0%   
Total assets Rs m27,770180,653 15.4%  
Interest coverage x468.826.6 1,763.5%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.90.7 136.1%   
Return on assets %11.810.6 110.8%  
Return on equity %16.320.9 77.9%  
Return on capital %25.822.0 117.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6,30642,683 14.8%   
Fx outflow Rs m5,25711,242 46.8%   
Net fx Rs m1,04931,441 3.3%   
CASH FLOW
From Operations Rs m4,3519,193 47.3%  
From Investments Rs m-787-9,737 8.1%  
From Financial Activity Rs m-1,884515 -365.8%  
Net Cashflow Rs m1,680-29 -5,793.1%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 8.3 173.5%  
FIIs % 14.6 5.9 247.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 11.0 95.5%  
Shareholders   15,184 44,069 34.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   MERCK LTD  CIPLA  ASTRAZENECA PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks ahead of Election Results; Realty Stocks Plummet(Closing)

Indian share markets settled around 2% lower today following a sell-off in the global markets and due to uncertainty over the outcome of state assembly elections tomorrow.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Dec 10, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS